False-positive results of the determination of bacterial endotoxins in drugs: the use of a β-glucan blocker
- Authors: Shapovalova O.V.1, Neugodova N.P.1, Sapozhnikova G.A.1
-
Affiliations:
- Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
- Issue: Vol 69, No 1 (2020)
- Pages: 5-9
- Section: Articles
- URL: https://journals.eco-vector.com/0367-3014/article/view/113275
- DOI: https://doi.org/10.29296/25419218-2020-01-01
- ID: 113275
Cite item
Abstract
Introduction. Assessment of the quality of drugs in terms of the indicator «Bacterial Endotoxins» has shown that along with the latter, β-glucans undergo enzymatic reaction with amebocyte lysate. This leads to false positive results in the (Limulus amebocyte lysate) LAL test, which poses a serious problem in the determination of pyrogenic impurities. There are 2 main sources of β-glucans in drugs: 1) excipients in the composition of a drug (for example, carmellose sodium, crosslinked sodium carboxymethylcellulose) and 2) technological impurities of the active ingredient at the drug production stage. Objective: to investigate the potentiating (reinforcing) effect of β-glucans in tests for bacterial endotoxins, to search and select a method for its elimination. Material and methods. The investigation objects were agents: Betamethasone, injectable suspension (7 mg/ml), and Inosine, injectable solution (20 mg/ml). Endotoxin-specific buffer (β-glucan blocker) was used to carry out the LAL test in gel-clot and chromogenic kinetic modifications. Results. The investigators considered the main causes of false results: potentiation (reinforcement) of a reaction of the LAL reagent with bacterial endotoxins due to the presence of β-glucans in the agents. Procedures were developed to eliminate the factors interfering with the LAL test in order to avoid false-positive results. Conclusion. Methodological approaches were elaborated to prevent the influence of a potentiating (reinforcing) interfering factor on the results of the LAL test
Full Text

About the authors
Olga Vladimirovna Shapovalova
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
Email: shapovalova@expmed.ru
Natalia Petrovna Neugodova
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
Email: neugodova@expmed.ru
Galina Alekseevna Sapozhnikova
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
Email: sapozhnikova@expmed.ru
References
- Bohn J.A., BeMiHe J.N. (1->3)-p-d-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydrate Polymers, 1995; 28(1): 3-14.
- FinkelmanM.(1,3)-|3-D-Glucan: Biological Properties and Implications for LAL Testing LAL UPDATE, 2005; 22 (2): 1 - 6.
- Sandle T. Pharmaceutical product impurities: considering beta glucans. [Electronic resource] Access mode: http://www. americanpharmaceuticalreview.com/Featured-Articles/152953-Pharmaceutical-Product-Impurities-Considering-Beta-Glucans/
- Williams K. Endotoxins Pyrogens, LAL Testing and Depyrogenation third Edition (Drugs and the Pharmaceutical Sciences), 2007: 198.
- Barton C., Vigor K., Scott R., Jones P.,Lentfer H., Bax H., Josephs D., Karagiannis S., Spicer J.Beta-glucan contamination of pharmaceutical products: How much should we accept? [Electronic resource] Access mode:https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC5069311/#
- Жилякова Е.Т., Попов Н.Н., Новикова М.Ю., Новиков О.О., Халикова М.А., Казакова В.С. Изучение физикохимических и технологических характеристик натрий карбоксиметилцеллюлозы с целью создания пролонгированных лекарственных форм с жидкой дисперсионной средой. [Электронный ресурс]. Режим доступа: http:// dspace.bsu.edu.ru/bit-stream/123456789/12393/1/Zhilyakova_Izuchen_Fiziko.pdf.
- Белясова Н.А. Микробиология. Минск: Высшая школа, 2012: 246. [Belyasova N. Microbiology. Minsk: Enter. SHK., 2012: 246 (in Russian)].
- Dobrovolskaia M. A., Neil S. Handbook of Immunological Properties of Engineered Nanomaterials. Vol. 1, 2013: 86 - 87.
- Государственная фармакопея Российской Федерации XIII изд., 2015: 956 - 973. [State Pharmacopoeia of the Russian Federation XIII ed., 2015: 956-73 (in Russian)].
Supplementary files
